ArticleApplied microbiology and biotechnology2025
New generation probiotics: combining probiotic and biotechnological potential of Kluyveromyces marxianus.
Article in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Non-Conventional Yeasts with Probiotic Potential: Diversity, Functional Role, Sustainable Bioprocessing and Local Relevance.Microorganisms · 2026Review
- Preliminary Functional Screening of AutochthonousMicroorganisms · 2026Article
- Integrated Fermentation Engineering Enables High-Level Leghemoglobin Production in Kluyveromyces marxianus via Metabolic Rewiring of Central Carbon Metabolism and Amino Acid Utilization.Biotechnology journal · 2026Article
- EngineeringFrontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Kluyveromyces marxianus has high biotechnological potential, particularly because it can utilize a wide range of substrates and grow faster than other yeasts. It has also attracted interest as a prospective probiotic; however, this application is still not well researched. Two K. marxianus strains with promising biotechnological properties and the proven ability to efficiently produce 2-phenylethanol (2-PE) and ethanol were examined in this study to evaluate their potential as probiotics. Yeasts WUT216 and WUT240 exhibited similar survival rates in a simulated human digestive system as the reference K. marxianus strain B0399 (DiarYeast®, LongLife, Milano, Italia). Additionally, the WUT yeasts revealed a high degree of adhesion to cancer and normal cell lines in vitro. Importantly, the WUT strains did not exhibit undesirable characteristics, such as mucolytic and hemolytic activities, and toxic effects on the Caco-2 cell lines in vitro and on Galleria mellonella larvae in vivo. Furthermore, K. marxianus strains displayed attractive probiotic properties, particularly high antioxidant potential, antifungal activity, and significant β-glucan content. This study also showed that the WUT yeasts are sensitive to the commercial antifungals, fluconazole, amphotericin B, and geneticin G418. Overall, the WUT240 and WUT216 exhibit similar probiotic properties to those of B0399. Thus, the WUT yeasts are not only promising producers of 2-PE and ethanol but also attractive probiotic candidates. Additionally, discrepancies in literature reports regarding the analyses conducted were noted, particularly in adhesion and autoaggregation tests. KEYPOINTS: • K. marxianus strains combine probiotic with its biotechnological potential • WUT yeasts may positively affect the host (antioxidants, β-glucan, antimicrobials) • Methodological differences hinder the comparison of potential probiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.